Results 11 to 20 of about 356,562 (324)

Drug-induced liver injury [PDF]

Clinical Medicine, 2016
Drug-induced liver injury (DILI) remains the most common cause of acute liver failure (ALF) in the western world. Excluding paractamol overdose, nearly all DILI encountered in the clinical setting is idiosyncratic in nature, since affected individuals ...
A, Amacher, Chalasani, Chen, Chien, El Sherrif, Hillman, Maggi, Russo, Sakaan, Studniarz, Suk, Yeong   +12 more
core   +9 more sources

Ivermectin drug induced liver injury

South African Medical Journal, 2023
Ivermectin remains a popular, albeit unproven, therapy used in both the prevention and treatment of COVID-19. We discuss a patient who developed jaundice and a liver injury 3 weeks after initiating ivermectin for COVID prevention.
Mark Sonderup, Washington Mudini, Wendy Spearman   +2 more
doaj   +4 more sources

Treatment of Drug-Induced Liver Injury

Biomedicines, 2022
Current pharmacotherapy options of drug-induced liver injury (DILI) remain under discussion and are now evaluated in this analysis. Needless to say, the use of the offending drug must be stopped as soon as DILI is suspected.
Rolf Teschke
doaj   +3 more sources

Drug-induced liver injury [PDF]

, 2010
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn Skoða/Opna(view/open)Drug-induced liver injury (DILI) is a well known adverse reaction of many drugs. Direct toxic liver damage is associated with paracetamol toxicity
Einar S. Björnsson
core   +3 more sources

Esterified Anabolic Androgen-Induced Liver Injury in a Hepatitis C Virus-Positive Patient: A CaseReport [PDF]

International Journal of Medical Students, 2015
Background: Cases of drug induced liver injury still perplex gastroenterologists due to its wide range of presentations that mimic acute and chronic liver conditions.
Kyrillus S. Shohdy, Rasmia M. El Gohary
doaj   +3 more sources

A virtual scalable model of the Hepatic Lobule for acetaminophen hepatotoxicity prediction [PDF]

npj Digital Medicine
Addressing drug-induced liver injury is crucial in drug development, often causing Phase III trial failures and market withdrawals. Traditional animal models fail to predict human liver toxicity accurately.
Stelian Camara Dit Pinto, Jalal Cherkaoui, Debarshi Ghosh, Valentine Cazaubon, Kenza E. Benzeroual, Steven M. Levine, Mohammed Cherkaoui, Gagan K. Sood, Sharmila Anandasabapathy, Sadhna Dhingra, John M. Vierling, Nicolas R. Gallo   +11 more
doaj   +3 more sources

Drug-induced liver injury [PDF]

Canadian Medical Association Journal, 2021
Drug-induced liver injury is estimated to have an incidence of 14–19 cases per 100 000 individuals.[1][1],[2][2] Although asymptomatic liver enzyme elevation is the most common presentation, drug-induced liver injury is the most common cause of acute liver failure in most Western countries,
Peter E. Wu, Alexander Kumachev
openaire   +4 more sources

Drug-induced liver injury [PDF]

Nature Reviews Disease Primers, 2019
Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that occurs either as a predictable event when an individual is exposed to toxic doses of some compounds or as an unpredictable event with many drugs in common use. Drugs can be harmful to the liver in susceptible individuals owing to genetic and environmental risk ...
Neil Kaplowitz, Guruprasad P. Aithal, Harshad Devarbhavi, Paul B. Watkins, Raúl J. Andrade, Michael Merz, Michael Merz, M. Isabel Lucena, Gerd A. Kullak-Ublick, Gerd A. Kullak-Ublick, Einar Bjornsson, Ayako Suzuki, Ayako Suzuki, Naga Chalasani   +13 more
  +11 more sources

[Drug-induced liver injury].

, 2006
Drug-induced liver injury (DILI) is common and nearly all classes of medications can cause liver disease. Most cases of DILI are benign, and improve after drug withdrawal. It is important to recognize and remove the offending agent as quickly as possible to prevent the progression to chronic liver disease and/or acute liver failure.
Toshihiko Ikeda
openalex   +5 more sources

The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. [PDF]

, 2014
BACKGROUND AND OBJECTIVE: Of three first-line anti-tuberculosis (anti-TB) drugs, isoniazid is most commonly associated with hepatotoxicity. Differences in INH-induced toxicity have been attributed to genetic variability at several loci, NAT2, CYP2E1 ...
A Tostmann, Atikaimu Wubuli, B Roy, B Roy, C Benichou, Corinne Merle, D Yee, DL Zhu, DS Huang, DW Hein, H Devarbhavi, HG Xie, HJ Cho, HJ De Rosa, HR An, HR An, I Vieira, J Meyer D, JH Wang, Jiayi Gu, Jinfeng Ma, JJ Saukkonen, JN Hirschhorn, JN Pande, JR Mitchell, JR Mitchell, Lei Yang, LG Possuelo, Long Ma, M Dossing, M Guo, M Guo, M Ingelman-Sundberg, M Ohno, M Runge-Morris, Mark Patrick Nicol, Mingqin Cao, N Vuilleumier, Paul Milligan, PD Bose, PD Roy, Qian Wang, Qian Wang, R Shakya, RC Strange, RL Teixeira, S Chatterjee, S Huang Y, S Russmann, S Sunahara, S Yamada, SH Kim, SH Kim, SK Sharma, SW Lee, SW Tang, T Mohri, T Sotsuka, T Wang, T Wang, T Yamamoto, V Leiro, Wei Liu, Weidong Wu, WJ Burman, WM Lee, WW Yew, Xia Zhu, Xiumei Xin, Xuemei Yao, XZ Lv, Y Chen, Yang Xiang, Ying Mao, YM Wu, Yongguang Li, YS Huang, YS Huang, YS Huang, YS Huang   +79 more
core   +13 more sources